The nude rat as an orthotopic model for cervical cancer

Katsuyuki Hamada, Norifumi Ueda, Masaharu Ito, Jack A. Roth, Michele Follen

Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

Department of Obstetrics and Gynecology, School of Medicine, Ehime University, Shitsukawa, Shigenobu, Onsen-gun, Ehime 791-0295, Japan

First Department of Pathology, School of Medicine, Ehime University, Japan

Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

Department of Obstetrics and Gynecology, The University of Texas Health Science Center, Houston, TX 77030, USA

Available online 26 September 2005

Abstract

Objective. The purposes of this study were to establish intracervical tumors of the nude rat as an orthotopic experimental model for human cervical cancer and to preliminary evaluate the effects of the adenoviral vector, Ad5CMV-p53, on orthotopic cervical tumor size.

Methods. Human cervical cancer SiHa and ME-180 cells were injected into the cervix of the nude rat. Four days later, 1 x 10^9 plaque forming units (PFU) of Ad5CMV-p53 were injected into the cervix. The rats were later sacrificed to determine cervical tumor size.

Results. Eight of ten nude rats developed SiHa cell tumors; all ten nude rats developed ME-180 cell tumors. Four of ten SiHa cell tumors metastasized to the pelvic cavity; no ME-180 cell tumors did. The growth of Ad5CMV-p53-infected cells was greatly suppressed. The ad5CMV-p53 treatment significantly reduced both cell tumor volumes in nude rat cervixes.

Conclusion. The nude rat cervix grows tumors similar to human cervical cancer tumors and makes an excellent experimental model. Transfection of cervical cancer cells with the wild-type p53 gene via Ad5CMV-p53 is a potential therapeutic approach to cervical cancer.

Keywords: Gene therapy; Cervical cancer; Orthotopic model; Nude rat; Animal models of cancer; ME-180

Introduction

Cervical cancer is the third most common malignancy in women worldwide and a major cause of mortality and morbidity in women in the developing world [1]. Despite progress in early detection and treatment, survival rates have not markedly improved in the last 10–20 years. Neoadjuvant chemotherapy following surgery or radiation therapy has been developed for locally advanced cervical cancer; however, further progress in controlling local and distant metastatic disease is needed. To gain further insight into and to develop new therapeutics for human cervical cancer and lymph-node metastasis in particular, an appropriate in vivo model is essential.

Early experimental models involving implanting human cervical cancer cells subcutaneously in athymic nude mice failed to yield metastatic disease. Orthotopic transplant models of human prostate cancer [2], pancreatic cancer [3], bladder cancer [4], lung cancer [5], colon cancer [6], breast cancer [7], and renal cell cancer [8] have demonstrated local tumor progression and distant metastases. These results provided some useful information to recognize the biological behavior of each cancer. Among gynecologic malignancies, orthotopic animal models of endometrial cancer [9] and ovarian cancer [10] have been reported, but that of cervical cancer remained to be established.

Clinical trials of cancer gene therapy, primarily using adenoviral vectors, have been developed for non-small cell lung cancer, head, and neck cancer, hepatocellular carcinoma, prostate cancer, ovarian cancer, and malignant
glioma [11]. In most clinical trials, vectors are locally injected to achieve the high level of gene expression in targeted cancer tissues. Subcutaneous tumor models in nude mice are commonly used to evaluate the in vivo antiproliferative effect of each vector. Our group has reported the use of the adenoviral vector in nude mice and in the rhesus monkey [12].

The modality of tumor progression in the subcutaneous tumor model is different from that in the orthotopic tumor model. The subcutaneous tumor model causes central tumor necrosis because of its low blood supply in the subcutaneous tissue, large tumor size because of its low potency of metastasis, and solitary tumor growth without invasion because of the lack of surrounding visceral organs. Cervical cancer invades the parametrial tissue first, regional lymph nodes second, and finally, distant organ sites. Invasion of cervical cancer to the surrounding visceral organs induces lethal complications, namely, renal failure by hydronephrosis, local bleeding, bladder metastasis, and rectal metastasis. The orthotopic cervical cancer tumor model follows the same progression; therefore, it might be considered adequate to evaluate new treatments.

We previously reported that adenovirus-p53 inhibits the growth of human cervical cancer subcutaneous tumors in nude mice by the induction of apoptosis [13]. For simulation of clinical trials of gene therapy for cervical cancer, we established for the first the orthotopic cervical cancer model in the athymic nude rat cervix. Human cervical cancer cells ME-180 and SiHa showed different tumor growth modalities. Here, we report the development of the orthotopic model of human cervical cancer and the effect of adenovirus-p53 on the growth of orthotopic cervical cancer cell tumors in the nude rat cervix.

Materials and methods

Experimental design

The overall design for these experiments is shown in Fig. 1.

Cell line and recombinant adenovirus

Human cervical cancer lines SiHa and ME-180 were obtained from the American Type Culture Collection (Rockville, MD). SiHa and ME-180 were infected with HPV 16 and HPV 68, respectively, and have wild-type p53. Cells were grown in RPMI medium supplemented with 10% heat-inactivated fetal bovine serum. The recombinant p53 adenoviral vector ad5CMV-p53 contains the cytomegalovirus promoter and wild-type p53 cDNA inserted into the E1-deleted region of modified adenovirus Ad5 [14]. This study used an adenoviral vector without the p53 cDNA (ad5CMV-poly A) as a control. The replication defective E1-deleted Ad5CMV-LacZ virus was used to determine transduction efficiencies. The 50% transduction efficiency was assessed by scoring 500 X-gal-positive cells in each of three replicate dishes and then determining the 50% of β-gal-positive blue cells. Viral stocks were propagated in 293 cells. All viruses were purified with double cesium chloride gradients using standard methods and titered with plaque assay [15].

Cell count assay

Cells were plated at a density of $5 \times 10^4$ cells/well in 12-well plates. Cells were infected with either Ad5CMV-p53 or the Ad5CMV-poly A viral control. Culture medium alone was used as the mock infection control. Each sample was analyzed in triplicate. After the sixth day of culture, cells were harvested and counted to determine the 50% growth inhibitory concentration (IC50). Cell viability was determined by trypan blue exclusion. The cells were inoculated at densities of $5 \times 10^4$ cells/well in each 12-well plate 24 h before infection.

Western blot analysis

Total cell lysates were prepared by lysing cell monolayers in plates with sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer after rinsing the cells with phosphate buffered saline. Each lane was loaded with 5 μg of cell lysate protein as determined by BCA protein assay (Pierce, Rockford, IL). After electrophoresis at 20 mA for 2 h, the proteins in the gels were transferred to Hybond-ECL membrane (Amersham Corp., Arlington Heights, IL). The membranes were then blocked with 1% dry milk and 0.1% Tween 20 (Sigma Chemical Co., St. Louis, MO) in phosphate buffered saline and
probed with two primary antibodies, mouse anti-human p53 monoclonal antibody D07 (DAKO) and mouse anti-human actin monoclonal antibody (Amersham). The membranes were developed according to the Amersham ECL protocol.

**Immunohistochemical analysis**

The AD5CMV-p53-injected SiHa cell tumors were analyzed to detect p53 protein expression. Tissue samples were fixed with 10% formalin for 24 h, and tissue sections were de-paraffinized. Tissue sections of SiHa cell tumors were treated with 3% H2O2 in methanol for 5 min. Immunohistochemical staining was performed with the Vectastain Elite kit (Vector Laboratories Inc., Burlingame, CA). The primary antibody was a mouse anti-human p53 monoclonal antibody D07 (DAKO Co., Carpinteria, CA), and the secondary antibody was a biotinylated goat anti-mouse immunoglobulin G (IgG) (Vector Labs). Avidin and biotinylated horseradish peroxidase macromolecular complex reagent (Vector Labs) was used to detect the antigen–antibody complex. The cells were stained with diaminobenzidine and then counterstained with Harris hematoxylin (Sigma Chemical Co., St. Louis, MO).

**Inhibition of orthotopic cervical tumor growth in nude rats**

To simulate the clinical trial of gene therapy for cervical cancer, an orthotopic cervical cancer model was established in the nude rats (Harlan, Houston, TX). The University of Texas M. D. Anderson Cancer Center guidelines for the care and use of the animals were followed. Ten million SiHa and ME-180 cells in 50 μl of RPMI medium were injected through an insulin syringe with a 27 1/2 gauge needle through the anterior vaginal fornix into the space among the anterior vaginal fornix, the lower limit of the bladder wall, and the anterior wall of the cervix. The vaginal portion of cervix is too hard and small for proper cell injection. Injection of cells through the posterior fornix into the cervix is often used to induce intraperitoneal injection through the pouch of Douglas. For these reasons, we injected cells through the anterior vaginal fornix into the space among the anterior vaginal fornix, the lower limit of the bladder wall, and the anterior wall of the cervix. The vaginal portion of cervix is too hard and small for proper cell injection. Injection of cells through the posterior fornix into the cervix is often used to induce intraperitoneal injection through the pouch of Douglas. For these reasons, we injected cells through the anterior vaginal fornix into the space among the anterior vaginal fornix, the lower limit of the bladder wall, and the anterior wall of the cervix. This resulted in good tumor growth. The 50 μl of Ad5CMV-p53 (1 × 10⁹ plaque forming unit, PFU), Ad5CMV-poly A (1 × 10⁹ PFU), or culture medium only was injected into the anterior cervix, which is the same portion that was previously injected with cervical cancer cells on days four, five, and six. Ten rats were used in each group. Eight weeks after the injection of cells, all rats were sacrificed and the tumor size was measured. Tumor volume was calculated assuming a spherical shape, with the average tumor diameter being the square root of the product of cross-sectional diameters.

**Results**

**Adenoviral infection of cervical cancer cells**

To determine the adenoviral transduction efficiency of SiHa and ME-180 cell line, cells were infected for 2 days with Ad5CMV-LacZ, an adenovirus that expresses the β-gal gene. There appeared to be a linear relationship between the number of infected cells and the number of adenovirus particles used in the infection. Both cell lines inoculated with a single dose of Ad5CMV-LacZ at 10 multiplicity of infection (MOI) or greater exhibited 100% blue cells (Fig. 2). The 50% transduction efficiencies of this vector were 0.3 and 1.1 MOI in SiHa and ME-180 cells, respectively, and both cells showed high transduction efficiencies.

**Expression of exogenous p53 in cervical cancer cells**

To determine the expression of the p53 protein in the Ad5CMV-p53-infected cervical cancer cells, Western blotting and immunohistochemical analysis were done using the mouse anti-human p53 monoclonal antibody D07. Western blot analysis was performed to compare the amount of p53 protein produced following the infection with Ad5CMV-p53 (Fig. 3A). Multiple dishes of SiHa cells were infected with Ad5CMV-p53 at 2 MOI. Following 12 h of incubation, the medium which contained virus was replaced with fresh medium, and each dish was cultured. The p53 protein expression peaked 3 days after infection and began to decline thereafter. However, the intensity of the p53 band at day 15 remained significantly higher than that in non-infected cells. Immunohistochemical analysis of SiHa cell tumors injected with Ad5CMV-p53 revealed characteristic staining of p53 protein in the nucleus 6 h after injection.
whereas AdSCMV-poly A-injected tumor cells failed to show p53 staining (Fig. 3B).

**Effect of exogenous p53 on cervical cancer cell growth**

The growth of the Ad5CMV-p53-infected SiHa and ME-180 cells was greatly suppressed when estimated by cell count assay 6 days after infection (Fig. 4). The cells were treated with Ad5CMV-p53, Ad5CMV-poly A, or medium only. The IC50 for SiHa and ME-180 is 4 and 15 MOI, respectively. Western blot and immunohistochemical analyses demonstrated that production of the p53 protein was significantly increased in Ad5CMV-p53-infected cells when compared with control cells, suggesting that the exogenous p53 mRNA may be efficiently translated. Human cervical cancer cells have a functional genotype equivalent to that of cells in which the p53 gene product is inactivated by the complex of the E6 protein with the p53 protein. The adenoviral vector is capable of mediating high levels of p53 expression, which are apparently sufficient to overcome the capabilities of the endogenous E6 to inactivate the p53 protein.

**Inhibition of orthotopic tumor growth in nude rat**

To address the feasibility of p53 gene therapy for orthotopic tumors, the efficacy of Ad5CMV-p53 in inhibiting tumor growth was evaluated in an orthotopic cervical cancer nude rat model using human cervical cancer SiHa and ME-180 cells. Eight of the ten rats treated with medium only developed SiHa cell tumors in the cervix, and four of the same ten rats developed metastatic lesions in the pelvic cavity as shown in Figs. 5A and E. All ten rats injected with ME-180 cells and treated with medium only developed ME-180 cell tumors in their cervixes; however, none developed metastatic lesions of the pelvic cavity as shown in Fig. 5B. Central necrosis, which frequently occurs in subcutaneous tumor models, is not generated in any of SiHa and ME-180 tumors as shown in Fig. 5C. Treatment with Ad5CMV-p53 significantly reduced sizes of SiHa cell tumors compared with those treated with medium only and Ad5CMV-poly A (P < 0.001, unpaired t test) (Figs. 5F and 6A). SiHa cell tumors appeared in five of ten animals after treatment with Ad5CMV-p53. Ad5CMV-p53 decreased metastases of SiHa cell tumors from four out of ten rats to one out of ten rats. The SiHa tumor sizes treated with medium only were not significantly different from those with Ad5CMV-poly A. On the other
hand, ME-180 tumors appeared in eight of ten animals after treatment with Ad5CMV-\(\text{p53}\) (Fig. 6B). Ad5CMV-\(\text{p53}\) significantly reduced ME-180 tumor sizes compared with medium only and AdCMV-\(\text{poly A}\) (\(P < 0.001\), unpaired \(t\) test). Metastasis of ME-180 cell tumor did not appear in any treated animals. The ME-180 tumor sizes treated with medium only were not significantly different from those treated with Ad5CMV-\(\text{poly A}\).

Comment

While an animal model of cervical cancer, such as the subcutaneous implantation of cervical cancer cells in a xenograft model [13], has been used in experimental oncology, there has been no report of an orthotopic cervical cancer model. In this article, we report an orthotopic cervical cancer model with metastases in the nude rat using two distinct human cervical cancer cell lines. The interpretation of experiments using subcutaneously implanted cervical tumors is limited because of different tissue-specific factors. The orthotopic bladder tumor model has been successfully used for evaluation of the efficacy of certain cancer treatments [16–20]. However, the tumor cell lines used to develop the orthotopic bladder tumor models, the number of instilled tumor cells, and the response variables were different. Currently, the SiHa and ME-180 cervical tumors implanted in nude rats are used for orthotopic tumor implantation. The amount of instilled cells was \(10^7\) cells in both tumors. Shapiro et al. [21] investigated the dose response of tumor implantation in the bladder tumor model and found a maximum tumor growth rate of >90% after instillation of \(10^6\) tumor cells, whereas instillation with \(2.5 \times 10^5\) cells led to a tumor growth rate of 30%. The rat cervix is distinctly difficult to inject tumor cells into because of its smaller size and harder tissue on the injection site than the bladder. Tumor instillation of \(<5 \times 10^6\) cells led to a decrease in the tumor growth rates in SiHa and ME-180 cell tumors. Therefore, we used \(10^7\) cells in both cell tumors. Low tumor volumes in SiHa cell tumors can compromise the evaluation of
orthotopic rat cervical cancer model. The model is a simple, cheap, and useful method to evaluate cancer models. From these results, we conclude that our approach might provide promising results for orthotopic cervical cancer studies.

HeLa, C4I, C4II, MW751, HT-3, and C33A are commonly used in the study of cervical oncology. In this study, we did not try these cell lines, but further investigation of them might be useful. Subcutaneous tumors without central necrosis and that the cervix has an abundant blood supply to grow large subcutaneous tumors without central necrosis. Collectively, these SiHa and ME-180 cell tumors orthotopically established in the nude rat cervix might be good candidates to simulate clinical progression and metastasis of cervical cancer and clinical treatment of cervical cancer by pharmaceuticals.

Successful tumor implantation is dependent on adequate injection into the anterior cervical surface through the anterior vaginal fornix. We tried traumatizing the cervical surface with a knife or a pair of scissors and the clumping of the vagina by agarose gel and clips. However, when using this method, the rats had a lower occurrence (20–30%) of intracervical tumors. Finally, we successfully employed an anterior intracervical injection to create the orthotopic cervical tumor.

Tumor outgrowth detected by abdominal palpation and vaginal inspection is thought to be the most probable response variable in this tumor model. However, these methods did not provide reliable parameters for assessing treatment effects on tumor growth. Using these parameters as response variables may give inadequate results because a reduced tumor growth in one group may be the result of successful treatment or may simply reflect failure of tumor implantation. To overcome these difficulties, other authors tried to monitor intravesical tumor growth and treatment effects by imaging methods like transrectal ultrasound [22] or resonance imaging [23,24]. These methods proved to be a suitable means for monitoring intraocular tumor growth, but each imaging procedure required anesthesia and catheterization. Apart from this, imaging methods, especially magnetic resonance imaging, are expensive. Consequently, the ME-180 tumor model is adequate to monitor treatment effects because 100% of animals established intracervical tumors. In addition to SiHa and ME-180 cells, HeLa, C4I, C4II, MW751, HT-3, and C33A are commonly used in the study of cervical oncology. In this study, we did not try these cell lines, but further investigation of them might provide promising results for orthotopic cervical cancer models. From these results, we conclude that our model is a simple, cheap, and useful method to evaluate the orthotopic rat cervical cancer model.

Most clinical trials of gene therapy for cancer deliver vectors by intratumoral injections. The innate host responses following administration of adenoviral vectors to humans result from the administration route [25]. Therefore, host responses after intracervical tumor injection might differ from those after subcutaneous tumor injection. These differences between injection sites could be further elucidated by using immunocompetent syngenic animal models. Human cervical cancer cells do not metastasize in immunocompromised subcutaneous animal models [12]. However, SiHa cell intracervical tumors metastasized to pelvic organs – probably to regional lymph nodes – and Ad5CMV-p53 suppressed SiHa cell tumor metastasis. Thus, the orthotopic SiHa cell tumor model could evaluate the efficacy of treatment methods for regional lymph-node metastasis. The uterine cervix encompasses many organs including blood vessels, lymph nodes, and the ureter, bladder, and rectum. These organs may develop a serious adverse reaction to the intracervical injection of adenovirus vectors. Therefore, it is important to investigate orthotopic cervical cancer models – and determine maximum tolerant dose of adenovirus – before using them to simulate clinical trials of gene therapy for cervical cancer in patients.

**Acknowledgments**

We would like to sincerely thank Dr. Hiroshi Konishi and Ms. Yoko Akimaru for their help in preparing the immunohistochemical slides.

This study was partially supported by a grant from the National Center Institute and the National Institutes of Health (R01 CA45187), gift to the Division of Surgery from Tenneco and Exxon for the Core Laboratory Facility, a grant from M. D. Anderson Cancer Center Support Core Grant (CA16672), grants from the Mathers Foundation, the University Cancer Foundation, and the Business Professional Women’s Fund, a sponsored research agreement with Intragen Therapeutics, Inc., a grant from the Ministry of Education, Science, Sports, and Culture, Japan, and a grant from the Ministry of Health and Welfare for a Comprehensive Strategy for Controlling Intractable Cancer, Japan.

**References**


